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Chapter I: 
Preface 
The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. 
Glutamate is a principal excitatory neurotransmitter in central nervous system (CNS). 
It causes strong excitation via activation of receptors at post synaptic membrane and 
elicits action potential when accumulation of receptor activity is occurred. It is also well 
recognized that glutamate receptor has a significant role in synaptic plasticity. It is 
therefore very important neurotransmitter in signal processing in CNS. Perturbation of 
glutamatergic neurotransmission could elicit various symptoms or diseases including 
seizures, abnormal movements, sensory abnormality, neuronal degeneration etc 
(Meldrum, 2000). For the prevention of trouble in glutamatergic neurotransmission, 
variety of receptors and transporters works in synapse (Featherstone, 2010). 
Glutamate receptors are divided into two subclasses. First subclass is metabotropic 
glutamate receptors.  These receptors are G-protein coupled receptor and have eight 
subtypes. The other one is ionotropic glutamate receptors which have ion channel in its 
structure. Binding of glutamate in ligand binding site of ionotropic glutamate receptors 
opens the channels directly. This receptor subclass includes three subtypes. They are 
named based on name of extrinsic ligands. The α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor is one of subtype of glutamate receptors. 
Remaining two receptors are N-methyl-D-aspartate (NMDA)- and kainate-type receptor. 
AMPA receptor distributes whole central nervous system and also peripheral nerves and 
tissues. The most of AMPA receptor in CNS localized at post synaptic neuronal membrane, 
especially post synaptic density. Channel gating kinetics of AMPA receptor is very fast 
and rapidly desensitized. It means AMPA receptor is machinery for very fast excitatory 
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synaptic transmission. The AMPA receptor is homo- or hetero-tetramer of receptor 
subunits named GluA1, A2, A3 and A4 (Mansour et al., 2001). Among four subunits, 
GluA2 is the determinant of Ca2+ impermeability of receptor (Hollman et al., 1991). 
GluA2 containing receptor is major receptor species, especially in glutamatergic 
projection neruons. In general GluA2 lacking Ca2+ permeable receptors exist in 
GABAergic interneurons (Geigaer et al., 1995; Janssen et al., 1998). It is also confirmed 
that composition of subunits can be altered in various neurons and synapsis according to 
physiological and pathological conditions (Janssen et al., 1998; de Lanerolle et al., 1998; 
Kessels and Malinow, 2009; Kobylecki et al., 2013; Liu and Zukin, 2007; Liu et al., 2010). 
GluA subunits have two alternative splice variants called Flip and Flop, which exhibit 
different channel properties. The expression levels of each splice variant are altered 
during development (Jakowec et al., 1998; Monyer et al., 1991), and change in response to 
various diseases or conditions (Kobylecki et al., 2013; Acosta et al., 2012; Eastwood et al., 
1997; Gitai et al., 2010; Guan et al., 2003; Kamphuis et al., 1992; Seifert et al., 2004). In 
addition, splice variants can change sensitivity to allosteric modulation of AMPA receptors 
(Partin et al., 1994; Quirk and Nisenbaum, 2003). AMPA receptors may also be associated 
with auxiliary subunits, such as transmembrane AMPA receptor regulatory proteins 
(TARPs), cornichon homolog (CNIH)-2, CNIH-3, cystine-knot AMPA receptor modulating 
protein 44 (CKAMP44), synapse differentiation-induced gene 1 (SynDIG1), suppressor of 
Lurcher (SOL)-1, SOL-2 and germ-cell-specific gene 1-like (GSG-1L) (Sumioka, 2013; 
Straub and Tomita, 2012). These auxiliary subunits can affect receptor kinetics and 
membrane trafficking of receptors, and their presence can change compounds from 
specific competitive AMPA receptor antagonists to partial agonists (Menuz et al., 2007; 
Huganir and Nicoll, 2013). Overall, receptor stoichiometry, splice variants and different 
auxiliary subunits can control the function of AMPA receptors according to the location of 
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the receptor, cell types, and condition of the cells. 
In terms of function, the AMPA receptor also has a significant role in the plasticity of 
synaptic strength. In general, synaptic strength is determined by trafficking of AMPA 
receptors into the post-synaptic active zone (Huganir and Nicoll, 2013,). Activity-
dependent insertion of the GluA1-containing AMPA receptor, followed by activation of 
NMDA receptors, is believed to be an initial step in synaptic potentiation. The resulting 
insertion of GluA2-lacking AMPA receptors into synapses leads to the stabilization of the 
synapse (Huganir and Nicoll, 2013; Plant et al., 2006). As the increased GluA1 expression, 
and presence of Ca2+-permeable receptors, has been confirmed under different conditions 
(Liu and Zukin, 2007; Chen et al., 2013; Hanley, 2014; Rajasekaran et al., 2013; Silverdale 
et al., 2010; Whitehead et al., 2013), AMPA receptors might be important in the 
progression of diseases, as well as their role in established diseases. 
 
AMPA receptor in disease. 
The AMPA receptor has very fundamental function in excitatory synaptic 
neurotransmission. Change of AMPA receptor mediated synaptic transmission could alter 
the function of neuronal network and causes various kind of symptoms and/or 
pathological changes. Impairments in synaptic plasticity have been implicated in multiple 
neuropsychiatric disorders (Citri and Malenka, 2008), supporting a potential role for 
therapeutic approaches to target AMPA receptors. In addition, given the role of glutamate 
as an excitatory neurotransmitter, conditions characterized by overexcitation of the CNS 
may represent putative therapeutic targets for AMPA receptor antagonists. This section 
provides an overview of AMPA receptors functions in the pathogenesis of epilepsy. 
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Epilepsy. 
Epileptic seizures are characterized by the disordered, rhythmic and synchronous firing 
of neurons in the brain, which results in transient behavioral changes and is often 
referred to as ‘epileptiform activity’ (McNamara, 1994). The balance of excitatory and 
inhibitory neural activity is crucial to maintaining neural network stability (Chagnac-
Amitai and Connors, 1989), and studies in hippocampal slices from guinea pigs have 
indicated that, in the presence of an antagonist of inhibitory GABA signalling, activation 
of just a single neuron can in turn activate multisynaptic excitatory pathways and 
ultimately lead to widespread synchronous discharge across a large population of neurons 
(Miles and Wong, 1983). It indicated importance of GABAergic system as a main player of 
inhibitory neuronal system. On the other hand, main machinery promoting neuronal 
excitability seems glutamatergic neuron. Variety of evidence suggested importance of 
AMPA receptor in pathophysiology of epilepsy. For example, domoic acid is a marine 
neurotoxin that causes neuronal toxicity through activation of AMPA and kainate 
receptors (Costa et al., 2010; Larm et al., 1997). In humans, domoic acid can produce 
amnesic shellfish poisoning, with severe intoxication leading to seizures, causing 
neuronal damage with a sequela of short-term memory loss (Costa et al., 2010; 
Teitelbaum et al., 1990). In 1995, Cendes et al. first reported a case of domoic acid 
intoxication in a patient who developed status epilepticus (SE) and subsequent 
spontaneous temporal lobe epilepsy. Such neuronal toxicity caused by domoic acid is very 
similar to the spontaneous seizures observed in the experimental kainic acid-induced 
rodent model of SE (Cendes et al., 1995; Lothman 1991). Overall, observations with 
domoic acid and kainate support a hypothesis that overactivation of AMPA receptors could 
have a role in the progression of hippocampal damage in temporal lobe epilepsy and 
refractoriness to drugs.  
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Findings of animal studies are consistent with a role for AMPA receptor activation in 
the development of epilepsy, including a study of the effects of Thorase, an AAA+ ATPase, 
which regulates the internalization of AMPA receptors. Genetic deletion of Thorase in 
mice resulted in increased cell surface expression of AMPA receptors, as well as death 
from a seizure-like syndrome between post-natal days 19 and 25 in most animals (Zhang 
et al., 2011). 
In humans, a pathophysiologic role for AMPA receptors in epilepsy has been indicated 
by a pharmacologic study of slices of lateral amygdala from patients with medically 
intractable temporal lobe epilepsy. In this study, blockade of AMPA receptors, but not 
NMDA receptors, inhibited interictal-like electrical activity, suggesting that AMPA 
receptors may have a role in abnormal electrical activity in the epileptic brain (Graebenitz 
et al., 2011). Supporting evidence was provided by an autoradiograph study, which 
showed an increased density of AMPA receptors in brain slices from patients with epilepsy 
(Graebenitz et al., 2011; Hosford et al., 1991).  
Studies in the human epileptic brain have also looked at AMPA receptor subunit 
expression: Ying et al (1998) demonstrated that expression of the GluA1 receptor subunit 
is elevated in the epileptic hippocampus, and positively correlates with axonal sprouting. 
Increased expression of the GluA1 subunit suggested an increase in levels of the 
homomeric GluA1 receptor, which exhibits high receptor conductance compared with the 
GluA2-containing Ca2+-impermeable heteromeric receptors (Coombs et al., 2012; Swanson 
et al., 1997). Of note, increased expression of GluA2-lacking Ca2+-permeable receptors is 
thought to occur before neuronal degeneration (Liu and Zukin, 2007; Grossman et al., 
1999). This is similar to the process of synaptic plasticity, during which insertion of the 
GluA1 homomeric receptor is also observed (Liu and Zukin, 2007) and, therefore, AMPA 
receptors may have a significant role in the pathophysiology of epilepsy: not only the 
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expression of seizures, but also the progression of epilepsy. 
Above noted evidence indicated that targeting AMPA receptors is a logical therapeutic 
approach to the development of new antiepileptic drugs. 
While the evidences indicating relationship between AMPA receptor and epilepsy 
existed abundantly. Therapeutic drugs for the treatment of epilepsy (antiepileptics 
(AEDs)) were not renewed. It was because of complexity of pharmacokinetic interaction of 
AEDs and its multiple mode of action. Second generation of AEDs were introduced in end 
of 20th century but major concept of drug discovery research was reduction of complexity 
in pharmacokinetic interactions and of safety (Stefan and Feuerstein, 2007). Major AEDs 
were categorized into channel modulators, GABA enhancers, presynaptic modulator or 
compound with multiple targets (Fig. 1). There was no selective postsynaptic glutamate 
antagonist before perampanel. 
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Figure 1. Mode of action of Antiepileptics 
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Chapter II: 
Creation of New AMPA antagonist 
Abstract 
This Chapter focuses on the discovery and preclinical profiling of perampanel as AMPA 
receptor antagonist. Many attempts were made to obtain drug inhibiting AMPA receptors 
for the treatment of various diseases but failed in the most of cases due to safety issue 
related to pharmacological effect and physicochemical property of chemical template. 
Requirement of new chemical template was considered essential to discover druggable 
AMPA antagonist. Chemical template of perampanel was discovered through High-
throughput screening (HTS). HTS hit compound was inhibited AMPA-induced 
intracellular Ca2+ increase in cortical neurons but not displaced [3H]AMPA binding 
suggesting non-competitive inhibition. Medicinal chemistry focused on the structure 
modification to achieve increase of intrinsic activity and improve metabolic stability. Here 
we discovered a series of 1,3,5-triaryl-1H-pyridin-2-one derivatives as antagonists of 
AMPA receptors. The structure–activity relationships for this series of compounds were 
investigated by manipulating individual aromatic rings located at positions 1, 3, and 5 of 
the pyridone ring. This culminated in the discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-
1,2-dihydropyridin-3-yl)benzonitrile (perampanel), a novel, non-competitive AMPA 
receptor antagonist that showed potent activity in an in vitro AMPA-induced Ca2+ influx 
assay (IC50 = 60 nM) and in an in vivo AMPA-induced seizure model (minimum effective 
dose = 2 mg/kg po). [3H]perampanel binding assay was developed for elucidation of mode 
of action of perampanel revealed non-competitive antagonism similar to known non-
competitive antagonists. 
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Introduction:  
Drug discovery research targeting glutamate receptors 
Research into the role of AMPA receptors in health and diseases in the late 1980s and 
into the 1990s was facilitated by the refinement of selective experimental agonists and 
antagonists for AMPA, kainate and NMDA receptors (Rogawski, 2011). However, research 
into the therapeutic potential of AMPA receptor antagonists was hampered by the 
challenging physical properties of the compounds investigated and their poor 
pharmacokinetic profiles.  
The first selective antagonists of non-NMDA ionotropic glutamate receptors were the 
quinoxalinedione derivatives, including CNQX and NBQX (Honore et al., 1988). These 
competitive antagonists bind to the glutamate-binding sites on the AMPA receptor, 
preventing glutamate from binding and activating the channel. However, they have 
limited selectivity for AMPA receptors over kainate receptors (Randle et al., 1992) and 
their physical properties prevented clinical development: for example, CNQX has good 
water solubility but limited ability to penetrate the blood-brain barrier (BBB). NBQX has 
poorly water solubility and low BBB permeability resulting precipitates in the kidneys 
(Rogawski, 2011; Weiser 2005).  
Next to be developed were the noncompetitive AMPA receptor antagonists. These 
agents do not prevent the binding of glutamate to the glutamate-binding site by their 
actions at a separate site in the receptor complex. The prototype noncompetitive AMPA 
receptor antagonist was the 2,3-benzodiazepine compound GYKI-52466, which shows 
modest intrinsic antagonistic effect, but good oral bioavailability and in vivo efficacy, 
indicating good BBB penetration (Weiser, 2005). GYKI-52466 was followed by more potent 
2,3-benzodiazepines; one of these compounds, talampanel (GYKI-53773 also known as 
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LY300164), progressed through preclinical investigation, and entered clinical trials for 
epilepsy and ALS (Chappell et al., 2002; Pascuzzi et al., 2010). Talampanel demonstrated 
significant reduction of seizure frequency in patient with refractory partial onset seizure 
(Chappell et al., 2002). However, further development was suspended, mainly because of 
suboptimal pharmacokinetic profile: talampanel has a half-life of approximately 6 hours, 
necessitating 3-times daily dosing, and its metabolism is inhibited by the antiepileptic 
drug, sodium valproate (Langan et al., 2003). Short half-life time of talampanel might 
cause high incidence of ataxia (Chappell et al., 2002). It also increased complexity of 
talampanel as therapeutic drug. 
An additional challenge in developing therapeutic AMPA receptor antagonists arises 
from the fundamental role of this receptor in CNS function. How can this receptor be 
targeted and inhibited without disrupting essential processes? Such concerns were 
perpetuated by animal studies, in which both competitive and noncompetitive AMPA 
receptor antagonists generally had neurological side effects at doses that were 
anticonvulsant (Yamaguchi et al., 1993). Furthermore, in the clinical setting, the 
competitive AMPA antagonist ZK200775 was associated with strong CNS-depressant 
effects on consciousness when evaluated in patients suffering from acute ischaemic stroke, 
leading to study termination (Walters et al., 2005). However, despite these challenges, the 
therapeutic potential and promise of AMPA receptor antagonists remained a very real and 
enticing prospect. 
Representative AMPA antagonists were listed in Figure 2. Problems of these AMPA 
antagonists were basically associated with structure related chemical property and 
pharmacokinetics. In addition the most of attempt of drug discovery research was started 
from known chemical template. In general, it is common approach to improve structure 
related problem but it has also limitation to overcome issues completely. We considered 
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that novel chemical structure is required to overcome the problem of existing AMPA 
antagonists. In addition, compound with new structure might have different mode of 
action. It enables us to find compound with different relationship between effects and side 
effects. 
 
High throughput screening and identification of seed compound 
Two high-throughput screening campaigns were run to discover a new chemical 
template for an AMPA receptor antagonist: the [3H]AMPA binding assay and the 
neuroprotection assay against AMPA-induced rat cortical neuronal cell death. The 
neuroprotection assay identified several promising compounds, including 2,4-diphenyl-
4H-[1,3,4]oxadiazin-5-one, which was selected for further development based on its 
dissimilarity to known AMPA receptor antagonists, as well as its potential for chemical 
modification. AMPA antagonistic effect of 2,4-diphenyl-4H-[1,3,4]oxadiazin-5-one was 
9.17 μM (IC50  in AMPA-induced Ca2+ influx assay) (Fig. 3). Following identification of 
drug seed compound, medicinal chemistry effort was continued to discover druggable 
compounds. In this chapter, I will describe path from hit to final compound in drug 
discovery research and character of perampanel. 
15 
 
Materials and Methods 
Reagents.  
Reagents were purchased from the following sources: GYKI52466, N-methyl-D-
aspartate (NMDA) and MK-801 from Sigma/RBI (St Louis, MO, USA); (RS)-AMPA from 
Tocris Cookson Inc. (Ellisville, MO, USA); tetrodotoxin (TTX) from Sankyo (Tokyo, Japan); 
and fura-2-AM from Dojin Chemical (Tokyo, Japan). Perampanel was synthesized by 
Eisai Co., Ltd. (Tokyo, Japan). 
 
Measurements of intracellular free calcium concentration. 
The cerebral cortex was excised from embryonic day 18 (E18) Wistar rats (Charles 
River Japan, Kanagawa, Japan) and dissociated by incubation for 30 min at 37°C in 
Ca2+/Mg2+-free Hanks’ balanced salt solution containing 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 3.3 mM D-glucose, 0.25% trypsin, 0.2 mg/mL 
DNase I, 50 units/mL penicillin and 50 μg/mL streptomycin. Cells were resuspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and plated at a density of 1×105 cells/well on 96-well test plates on an astrocyte 
feeder layer. Cultures were maintained without exchange of medium for 7–17 days at 
37°C in a 5% CO2/95% air incubator (Abe et al., 1990). 
Changes in intracellular free Ca2+ concentration ([Ca2+]i) were measured in rat cortical 
neurones using the fluorescent Ca2+ indicator dye fura-2, as previously described (Fischer 
et al., 2000). Cells were incubated with fura-2 AM (10 μM) in a 5% CO2/95% air incubator 
at 37°C for 2 hours and washed with Ca2+ assay buffer (140 mM NaCl, 5 mM KCl, 2 mM 
MgCl2, 3 mM CaCl2, 24 mM D(+)-glucose, 10 mM HEPES, 1 µM MK801; pH 7.4 adjusted 
with NaOH for AMPA). Changes in [Ca2+]i were determined by fluorimetry (Fluorescence 
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Drug Screening System, Hamamatsu Photonics, Shizuoka, Japan) by measuring changes 
in the fluorescence emission ratio of fura-2 after consecutive excitations at 340 and 380 
nM wavelengths. AMPA(1 µM) was used for drug screening. For the characterization of 
perampanel, AMPA (2 µM) and NMDA (100 μM) were used to stimulate specific receptor 
subtypes, and the inhibitory effects of perampanel, GYKI52466, and MK-801 on these 
responses were assessed. Ca2+ assay buffer without MgCl2 or MK-801 was used in assays 
involving NMDA. 
 
Liand binding assay. 
Ligand binding assays were conducted in extracts or membrane fractions obtained from 
various tissues and from cell lines expressing the respective targets. A radioactively 
labeled ligand specific for each target was used at a concentration approximately 
equivalent to the ligand's Kd, and perampnel was added at a concentration of 1.25 μM. In 
the positive controls, ligands with known Kis for each target were added (listed as 
"reference compound" in the table 3). After incubation for a period of time sufficient to 
allow equilibrium binding, the ratio of bound and unbound radioactivity was measured. 
Binding without perampanel was used as control. From this ratio the % inhibition of 
binding by perampanel was determined. Data are the result of two experiments. 
 
In vivo antagonism of AMPA receptor (AMPA-induced seizure) . 
Male ddY mice 4 or 5 weeks old obtained from Japan SLC, Inc (Shizuoka, Japan) were 
used in the study. Test compounds or perampanel were suspended in 0.5% MC and were 
orally administered 1 h before each test. AMPA was dissoleved in 0.9% NaCl at 0.4 mM. 
Intra-cerebral ventricular infusion AMPA was made according to the method described by 
Turski (1992). Briefly, 30 gauges needle was used and introduced at coronal suture of mice 
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skull. Depth of insertion was controlled by stopper at 3.5 mm from skull surface then mice 
are released in the arena to allow spontaneous activity. AMPA was infused with syringe 
pump (Model CMA100; Carnegie Medicine AB, Stoclkholm, Sweden) at the rate of 
5 μl/min. Duration until initial sign of clonic seizure was measured as endpoint. Mice that 
did not show clonic seizure within 180 seconds were recorded as having a 180-second 
latency time. The lowest dose providing statistically significant prolongation of latency 
was defined as the MED. 
 
In vitro metabolism study in liver microsomes.  
Hepatic intrinsic clearance (CLint) was calculated from the substrate disappearance 
rate in liver microsomes. Each compound (0.1 µM) was incubated with a reaction mixture 
(150 µL) consisting of mouse, rat, or human liver microsomal protein (0.2 mg/mL) in 100 
mM potassium phosphate buffer (pH 7.4) and 0.1 mM EDTA. After pre-incubation for 5 
min at 37ºC, the enzyme reaction was initiated by adding an NADPH-generating system 
(0.33 mM β-NADP+, 8 mM glucose-6-phosphate, 6 mM MgCl2, and 0.1 unit/mL glucose-6-
phosphate dehydrogenase). After incubation of the microsomal matrix for 15 min at 37ºC, 
150 µL internal standard (1 µM propanolol in methanol/acetonitrile [3/7, v/v]) was added 
to the reaction mixture and mixed vigorously. After centrifugation, the supernatant was 
subjected to LC/MS/MS analyses in positive ion mode with multiple reaction monitoring. 
For the characterization of perampanel, similar assay but slightly different asaay 
system was used. Liver microsomes from human, rat, dog, and monkey were purchased 
from Xenotech, LLC (Lenexa, Kansas, USA). Microsomes (0.5 mg/mL microsomal protein) 
were incubated with perampanel (0.03 µg/mL), EDTA (0.1 mM), an NADPH-generating 
system (0.33 mM β-NADP+, 0.8 mM glucose 6-phosphate, 0.1 unit/mL glucose 6-
phosphate dehydrogenase, 6 mM MgCl2), and phosphate buffer (100 mM; pH 7.4) for 20 
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min at 37°C, and reactions were terminated by addition of acetonitrile. The residual 
concentration of perampanel was determined by liquid chromatography–tandem mass 
spectrometry (LC-MS/MS) with multiple reaction monitoring operated in the positive 
ionization mode. 
 
Pharmacokinetic parameters. 
For charactaerization of pharmacokinetics, perampanel was administered as follows: to 
fasted male Sprague Dawley rats (n = 4), intravenously (bolus in 0.25 M HCl in saline) or 
orally (in 0.33 M HCl) at 1 mg/kg; to fasted male beagle dogs (n = 3), intravenously (bolus 
in 0.1 M HCl in saline) or orally (in 0.1 M HCl) at 0.1 mg/kg; and to fasted male 
cynomolgus monkeys (n = 4), intravenously (bolus in 0.1 M HCl in saline) or orally (in 0.1 
M HCl) at 0.03 mg/kg. Blood samples were collected from rats via the jugular vein (0.25 
mL), and from dogs via the cephalic vein (1 mL), and from monkeys via the 
cephalicfemoral vein (1 mL and 0.5 mL, respectively) using heparinized syringes. For all 
species, timepoints for blood collection were pre-dose, 5 min, 15 min, 30 min, 1, 2, 4, 6, 8 
and 24 hr after intravenous dosing, and 15 min, 30 min, 1, 2, 4, 6, 8 and 24 hr after oral 
dosing. Samples from monkey were also taken at 12 h. Plasma was obtained by 
centrifugation and deproteinized using methanol: 60% perchloric solution (500:1 v/v). The 
plasma concentration of perampanel was determined by high-performance liquid 
chromatography with fluorescence (HPLC-FL). Pharmacokinetic parameters for 
perampanel were calculated by model independent analysis (WinNonlin, Pharsight, North 
Carolina, USA). For assessment of brain penetration of brain samples were obtained from 
male ddY mice and male Sprague−Dawley rats after oral administration. Cerebrospinal 
fluid (CSF) samples were collected from mice by cisternal puncture after intraperitoneal 
administration. Brain was homogenized in two volumes of water, and the brain 
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homogenates and CSF samples were processed and analyzed in a manner similar to that 
for plasma samples. 
 
Radiolabeled perampanel binding assay. 
Rat forebrain membranes were prepared as previously described (Balannik et al., 2005). 
Forebrains of Sprague Dawley rats were homogenized in ice-cold 0.32 M sucrose 
containing 0.1 mM EGTA (pH 7.4) and centrifuged at 1000 x g for 10 min. The 
supernatant was centrifuged at 30,000 x g for 20 min and the resulting pellet was lysed in 
1 mM EGTA/Tris-HCl (pH 8.0) and centrifuged at 30,000 x g for 20 min to collect the 
membranes. This lysis and centrifugation step was repeated, and the pellet was 
resuspended in 50 mM Tris-HCl buffer (pH 7.4). Membranes were sonicated and washed 
three times, resuspended in 50 mM Tris-HCl buffer (pH 7.4) and stored at -80ºC. Before 
use, aliquots were thawed and sonicated, washed twice in 50 mM Tris-HCl buffer and 
resuspended at 0.5 mg/mL with 50 mM Tris-HCl buffer (pH 7.4).  
Specific and non-specific binding of [3H]perampanel to rat forebrain neuronal 
membranes was measured in the presence and absence of various glutamate receptor 
agonists and antagonists. Briefly, membranes and compounds were mixed with 50 nM 
[3H]perampanel (specific activity 1.92TBq/mmol) and incubated for 1.5 hours at 4°C. 
Samples were filtered onto Whatman GF/B glass-fiber filters presoaked in 0.3% 
polyethyleneimine and washed three times with 2 mL ice-cold 50 mM Tris-HCl buffer (pH 
7.4) using a Brandel M-30R cell harvester. Radioactivity was quantified by liquid 
scintillation counting. Non-specific binding was determined by incubation with 15 μM 
perampanel. Specific binding was determined by subtraction of non-specific binding from 
total binding.  
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Statistical analysis 
For in vitro studies, values for Ca2+ response and radioligand binding were expressed as 
mean ± SEM (standard error of the mean). IC50 values were determined by regression 
analyses. The differences between the control group and the perammpanel groups were 
analyzed by non-parametric one-way analysis of variance (ANOVA) followed by the 
Dunnett type multiple comparison test. A value of p<0.05 (2-sided) was considered 
statistically significant. Statistical analysis was conducted using the software package, 
SAS 6.12 (SAS Institute Japan Ltd., Tokyo, Japan). 
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Results 
Identification of Perampanel. 
The 2,4-diphenyl-4H-[1,3,4]oxadiazin-5-one was a selected hit compound in high 
throughput screening with neuronal cell death assay. It was not shown displacement of 
[3H]AMPA binding therefore hit compound was considered noncompetitive antagonist. 
This compound has relatively small molecular size therefore it was considered that 
addition of chemical moiety for the improvement of properties as a drug could be accepted. 
The first significant milestone in medicinal chemistry was replacement of oxadiazinone 
to pyridone. It reduced AMPA antagonistic activity but subsequent insertion of aromatic 
ring to the position 1 of pyridone ring significantly improved both AMPA antagonist 
activity and metabolic stability in liver microsome. Improve of metabolic stability was 
considered due to masking effect of the acidic hydrogen by insertion of another phenyl 
group to the pyridone template. This 1,3,5-triaryl-1H-pyridin-2-one template showed 
suitable chemical tractability for further medicinal chemistry effort. It was also a reason 
of selection as drug lead compound. 
Additional optimization of the 1,3,5-triaryl-1H-pyridin-2-one template was conducted by 
focusing on manipulation of the individual aromatic rings located at positions 1, 3, and 5 
of the pyridone ring to yield a series of potent and selective noncompetitive AMPA 
receptor antagonists. Finally 2 ‑ (2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-
yl)benzonitrile (Perampanel) was identified as potent AMPA antagonist (Fig. 4, Table 1). 
 
Characterization of perampanel. 
As a results of medicinal chemistry effort, perampanel (2-(2-Oxo-1-Phenyl-5-Pyridin-2-
yl-1,2-Dihydropyridin-3-yl)Benzonitrile) was identified as an orally active, non-
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competitive AMPA antagonist (Fig. 5). Pharmacological actitivty of perampanel will be 
described in this part. 
AMPA receptor antagonism. 
Rat cortical neurones were used to determine the effects of perampanel on AMPA 
receptor function, as measured by AMPA-induced increases in [Ca2+]i. Perampanel 
inhibited AMPA-induced increases in [Ca2+]i in a concentration-dependent manner (IC50 
93 nM vs. 2 µM AMPA; 95% CI, 40–150 nM) (Fig. 6A).  
Perampanel shifted dose response curve of AMPA-induced Ca2+ influx at 0.3 μM but 
suppressed maximal effect of AMPA at 1 μM. This behavior of antagonist often observed 
in non-competitive modulator of receptor (Fig. 6B).  
We assessed binding site of perampanel using [3H]perampanel. The Kd for 
[3H]perampanel binding to rat forebrain membranes was 59.8 ± 5.2 nM and the Bmax was 
3.2 ± 0.1 pmol/mg (n = 4) (Figure 7). The glutamate receptor agonists glutamate (1 mM) 
and AMPA (0.1 mM), and the competitive glutamate receptor antagonist NBQX (0.1 mM) 
did not significantly reduce [3H]perampanel binding to rat forebrain membranes (Figure 
8A). However, [3H]perampanel binding was affected AMPA receptor channel gating status. 
Application of AMPA and cyclothiazide to AMPA receptor biased channel gating state 
toward open. In this condition affinity of perampanel to AMPA receptor was reduced (Fig. 
8, Table 2). The other non-competitive AMPA antagonists, “CP465,022” and “GYKI52466” 
also showed similar change of affinity related to channel gating status (Balannik et al., 
2005). As expected, [3H]perampanel binding was displaced by the noncompetitive AMPA 
receptor antagonists CP465022 (IC50 21.1 ± 1.4 nM; Ki 11.2 ± 0.8 nM; mean ± SEM; n = 4) 
and GYKI52466 (IC50 23.3 ± 1.9 µM; Ki 12.4 ± 1 μM; mean ± SEM; n = 4) (Fig. 9).  
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Selectivity.  
In rat cortical neuron culture, application of NMDA can cause Ca2+ influx through 
NMDA receptor. The effects of perampanel on NMDA receptor activity induced by NMDA 
(100 μM) were determined. Perampanel inhibited NMDA-induced increases in [Ca2+]i by 
18%, but this change was not statistically significant even at the highest concentration 
tested (30 μM). In contrast, the noncompetitive NMDA receptor antagonist MK801 (1 μM) 
markedly inhibited NMDA-induced increases in [Ca2+]i by approximately 85% (Figure 10). 
Effect on other physiologically important molecules like receptors, enzymes and 
transporters were confirmed using ligand binding assay. It was conducted at Novescreen 
using validated method in their laboratory. Perampanel at 1.25 μM did not exert more 
than 50% displacement in binding assay. It strongly suggested that perampanel does not 
interact with other physiologically important molecules (Table 3). 
 
In vivo AMPA antagonism. 
Perampanel prolonged latency to seizure onset. Significant prolongation of latency was 
observed at 2 mg/kg and above (Fig. 11). It indicated oral availability and AMPA 
tanatagonistic effect in in vivo.  
 
Pharmacokinetics. 
Pharmacokinetic parameters for perampanel in rat, dog, and monkey are summarized 
in Table 5. Values for half-life, area under the curve (AUC) and bioavailability of 
perampanel were higher in dog and monkey than in rat; clearance values were lower in 
dog and monkey than in rat. Brain-to plasma concentration ratios were evaluated in mice 
and rats. The ratios were 1.06 and 1.14 in mice and rats, respectively. Furthermore, the 
cerebrospinal fluid (CSF) concentration was measured in mice, and the CSF concentration 
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to unbound plasma concentration ratio was calculated to be 1.14. 
 
In vitro metabolic stability of perampanel. 
Metabolic stability of perampanel in the presence of rat, dog, monkey, or human liver 
microsomes was examined in vitro. The residual amount of perampanel remaining after 
20 minutes of incubation with rat, dog, monkey, or human microsomes was 69.9%, 54.6%, 
85.3%, and 100.2%, respectively (n = 2). 
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Discussion and Conclusion 
High-through put screening had been conducted to obtain novel chemical template of 
AMPA antagonist. Among hit compound in HTS, 2,4-diphenyl-4H-[1,3,4]oxadiazin-5-one 
was selected as start compound for medicinal chemistry. It was not bind AMPA receptor in 
[3H ]AMPA binding assay therefore this compound inhibit AMPA receptor non-
competitively.  
Modification of chemical structure aiming to improve intrinsic activity and metabolic 
stability discovered 1,3,5-triaryl-1H-pyridin-2-one template. Further derivatization of 
position 1,3,5 aromatic ring enable us to find 2 ‑ (2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-
dihydropyridin-3-yl)benzonitrile (Perampanel).   
In in vitro studies, perampanel potently inhibited AMPA-induced increases in 
intracellular [Ca2+]i in cultured rat cortical neurones, but did not significantly inhibit 
MK801-sensitive NMDA-induced Ca2+ responses, suggesting that perampanel is a 
selective AMPA receptor antagonist. Selectivity of perampanel for AMPA receptors over 
NMDA receptors may be an important feature clinically as NMDA receptor antagonists 
are known to produce psychoactive effects, including schizophrenia-like symptoms and 
cognitive impairment (Meldrum and Rogawski, 2007). 
Although perampanel inhibited AMPA-induced functional responses, [3H]perampanel 
binding to rat forebrain membranes was only slightly reduced by high concentrations of 
glutamate, and was unaffected by the competitive AMPA receptor antagonist NBQX. 
Furthermore, perampanel at a concentration of 1.25 µM did not inhibit [3H]AMPA binding. 
These data suggest a noncompetitive interaction of perampanel with the AMPA receptor. 
In addition, perampanel binding was reduced in a concentration-dependent manner by 
the selective noncompetitive AMPA receptor antagonists GYKI52466 and CP465022, 
26 
 
suggesting a common binding site between perampanel and these compounds. In line with 
these findings, other studies have demonstrated common binding sites between 
noncompetitive AMPA receptor antagonists on the AMPA receptor. CP465022 and 
GYKI53655 are reported to share a binding site at the interface between the glutamate 
binding core and the channel region of the AMPA receptor (Balannik et al., 2005). Binding 
to this site is thought to stabilize the resting state of the channel and disrupt channel 
opening in response to agonist binding (Balannik et al., 2005). 
Perampanel showed oral efficacy in AMPA-induced seizure model. It indicated that 
perampanel act as AMPA antagonist also in vivo. Effective dose of peramapanel in this 
animal model was relatively low. It suggested that perampanel could have good 
pharmacokinetic properties in animal. Actually prampanel showed favorable 
pharmacokinetic profile including brain penetration in animals.  
Prediction of pharmacokinetics in human is important in drug discovery research. For 
the purpose, metabolic stabilities in mice, rats, dogs, monkeys and human microsomes 
were examined. The results clearly indicated that metabolic rate in human should be very 
low suggesting long half life time. It is well known that sedative drugs often show 
tolerance in repeated use (Zapantis and Leung, 2005). Gradual increase of plasma 
concentration due to long half life time expected to help development of tolerance in 
clinical use.  
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Figure 2. Kown AMPA antagonists 
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Figure 3. Screening flow finding for new chemical template. 
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Figure 4. Flow of medicinal chemistry from hit compound of high throught put screening 
to perampanel. 
 
Table 1. Inhibitory activity against AMPA-induced Ca2+ influx and metabolic stability in 
liver microsome. 
 
30 
 
 
Figure 5. Perampanel. 
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Figure 6. AMPA antagonistic activity of perampanel in AMPA-induced Ca2+ influx 
assay. 
A. Inhibition of AMPA-induced Ca2+ influx by perampanel in cultured rat cortical 
neuron. Perampanel inhibited Ca2+ influx induced by 2 μM of AMPA with an IC50 
value at 93 nM.  B. Perampanel at 1 μM dampened peak Ca2+ response of AMPA. 
 
 
  
32 
 
 
 
Figure 7. [3H]perampanel binding.  
A. [3H]Perampanel binding. Filled circle indicated total binding. Open square 
indicate nonspecific binding displaced with 15 µM perampanel. Filled triangle 
indicated specific binding of [3H]perampanel binding assay. 
B. Schatchard plot of [3H]perampanel binding. 
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Figure 8.  [3H]Perampnael Binding, interaction with competitive 
agonist/antagonist binding site.  
A.  Perampanel binding was not displaced by excessive amount of competitive 
antagonist and agonist. (n=3) 
B.  Affinity of perampanel was affected by ion channel state (close or open). Filled 
square is control perampanel binding (close state). Open triangle indicate 
perampanel binding with 100 μM AMPA and 100 μM cyclothiazide (open state). 
 
 
 
 
Table 2.  Channel state dependent change of [3H] perampanel binding. 
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Figure 9. Displacement of [3H]Perampanel binding with known non-competitive 
AMPA antagonists. Calculated values for each compound is following. 
CP465022, IC50 21.1 ± 1.4 nM; Ki 11.2 ± 0.8 nM; n = 4 
GYKI52466, IC50 23.3 ± 1.9 μM; Ki 12.4 ± 1 μM; n = 3 
Data are represented as mean ± SEM. 
 
 
 
 
Figure 10. inhibitory effect of perampanel against NMDA -induced Ca2+ influx.  
Inhibition of NMDA-induced Ca2+ influx by perampanel in cultured rat cortical 
neuron(n=10). Perampanel inhibited Ca2+ influx by 18% at 30 μM.  Inhibitory effect 
was not reached statistical significance.  
 
  
35 
 
Table 3. Inhibitory effect of perampanel on binding with various ligands. 
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Figure 11. Perampanel antagonized in vivo AMPA receptor agonist effect. 
Perampanel or vehicle were administered one hour before test. 
Data are represented as mean ± SEM (n=9-10). * for p<0.05 vs vehicle (Dunnett’s 
test) 
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Table 4. Pharmacokinetic parameters for perampanel in rat, dog, and monkey.   
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Chapter III: 
Charaterization as therapeutic agents for epilepsy 
Abstract 
Treatment refractory epilepsy is one of a target for drug discovery research. It is 
considered that AMPA receptor has contribution on pathophysiology of treatment 
refractory epilepsy. Perampanel is the novel non-competitive AMPA antagonist. To assess 
the activity of perampanel as antiepileptic drug, Activity of orally administered 
perampanel was examined in amygdala-kindled rats and in mice exhibiting audiogenic, 
maximal electroshock (MES)–induced, pentylenetetrazole (PTZ) –induced, or 6 Hz-
induced seizures. In mice, perampanel showed protective effects against audiogenic, MES-
induced, and PTZ-induced seizures (ED50s 0.47, 1.6, and 0.94 mg/kg, respectively). 
Perampanel also inhibited 6 Hz electroshock-induced seizures without changing efficacy 
by increasing stimulus intensity. In amygdala-kindled rats, perampanel significantly 
increased afterdischarge threshold (p < 0.05 vs. vehicle), and significantly reduced motor 
seizure duration, afterdischarge duration, and seizure severity recorded at 50% higher 
intensity than afterdischarge threshold current (p < 0.05 for all measures vs. vehicle). In 
genetic absence epilepsy in rats from Strasbourg (GAERS), perampanel up to 10 mg/kg 
did not show significant effect. Perampanel caused dose dependent motor impairment in 
both mice (TD50 1.8 mg/kg) and rats (TD50 9.14 mg/kg), as determined by rotarod tests. In 
mice, the protective index (TD50 in rotarod test/ED50 in seizure test) was 1.1, 3.8, and 1.9 
for MES-induced, audiogenic, and PTZ-induced seizures, respectively. These data suggest 
that perampanel is an orally active, noncompetitive, selective AMPA receptor antagonist 
with potential as a broad spectrum antiepileptic agent. 
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Introduction 
Epilepsy is a common neurologic disorder that manifests as recurrent seizures and 
affects approximately 0.5–1% of the general population(Abu Saleh and Stephen, 2008; 
Ngugi et al., 2010). While many second- and third-generation antiepileptic drugs (AEDs) 
have been introduced into clinical practice over the past 20 years, there still remains a 
significant unmet medical need to control seizures, as evidenced by the 15–35% of all 
patients with epilepsy who fail to achieve long-term remission (Shorvon and Goodridge, 
2013). In order to best address this unmet need, AED research must keep abreast of 
advances in technology and basic science. To this end, the technical and methodological 
issues of AED development have been discussed recently as part of several working 
groups (French et al., 2013; Galanopoulou et al., 2013; Wilcox et al., 2013).  
The development of AEDs with modes of action (MOAs) based on a pathophysiologic 
understanding of the condition may represent a rational strategy. With this in mind, the 
underlying pathophysiologic condition in seizure disorders is believed to be the imbalance 
of excitatory and inhibitory neuronal activity (Lason et al., 2013; McCormick and 
Contreras, 2001). Glutamate and gamma-aminobutyric acid (GABA) are the major 
neurotransmitters that contribute to excitatory and inhibitory activities in the central 
nervous system (CNS), and both have been implicated in seizure development. As 
described, AMPA receptor has significant contribution in the pathophysiology of epilepsy 
and could have a contribution on development of epilepsy. Therefore antagonist of AMPA 
receptor could have a significant role in the treatment of epilepsy. It is known that 
efficacy in preclinical seizure models could be translated into efficacy in human patients. 
Anti-seizure effect of perampanel is described for the consideration of efficacy profile in 
human.  
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Materials and Methods 
Generalized tonic-clonic seizures (MES-induced seizures). 
Electroshock seizures were induced in 4-week-old male ddY mice obtained from Japan 
SLC, Inc (Shizuoka, Japan). Animals were dosed orally with perampanel (0.75, 1.06, 1.50, 
or 2.12 mg/kg), carbamazepine (9.2, 13, 18.4, or 26 mg/kg), sodium valproate (284, 400, 
567, or 800 mg/kg) or vehicle 1 hour prior to electrical stimulation. All drugs were 
suspended or dissolved in 0.5% methylcellulose solution. Electrical stimulus (80 V) was 
applied to both corneas for 0.4 sec. An occurrence of electroshock-induced tonic extension 
(TE) was defined as a hindlimb TE lasting >1 sec following stimulation. ED50 and 95% 
confidence intervals (CI) for TE inhibition were calculated by regression analyses. 
 
Absence or myoclonic seizures (Pentylenetetrazole (PTZ)-induced seizures) . 
PTZ-induced seizures were generated in 9-week-old male ICR mice obtained from CRJ, 
Inc. (Kanagawa, Japan). Animals were dosed orally with perampanel (0.75, 1.5, or 3 
mg/kg), carbamazepine (100 mg/kg), sodium valproate (150, 300, or 600 mg/kg), or vehicle 
30 min prior to initiation of seizures. All drugs were suspended or dissolved in 0.5% 
methylcellulose solution. Seizures were then induced by subcutaneous injection of PTZ 
(90 mg/kg). An occurrence of PTZ-induced seizure was defined as a seizure of at least 3 sec 
duration within 30 min of PTZ administration. 
 
Reflex seizures (Audiogenic seizures).  
Audiogenic seizures were induced in 3-week-old male DBA/2J mice obtained from CLEA 
Japan, Inc. (Tokyo, Japan). Mice were dosed orally with perampanel (0.3, 1, or 3 mg/kg), 
carbamazepine (1, 3, or 10 mg/kg), sodium valproate (30, 100, or 300 mg/kg), or vehicle 1 
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hour prior to initiation of seizures. All drugs were suspended or dissolved in 0.5% 
methylcellulose solution. Mice were then habituated for 1 min in an observation box and 
exposed to sound stimulation (11 kHz, 115 dB) for 1 min or until TE occurred. An 
occurrence of sound-induced seizure was defined as a hindlimb TE lasting >1 sec during 
sound stimulation.  
 
Psychomotor seizures (6-Hz electroshock-induced seizures). 
Perampanel (0.5, 1, 2 or 4 mg/kg) or vehicle (0.5% methylcellulose) was orally 
administered to 9-week-old male ICR mice 1 hour prior to test. An electrical stimulus (6 
Hz, 0.2 msec rectangular pulse, 3 sec duration, 32 or 44 mA) was applied to both corneas 
and an occurrence of seizure was defined as appearance of immobility or stun, forelimb 
clonus, twitching of the vibrissae, and an elevated (or Straub) tail (Barton et al., 2001). 
 
Motor coordination (Rotarod test). 
Six-week-old male Sprague Dawley rats and 8-week-old male ICR mice were obtained 
from Charles River Japan, Inc. (Kanagawa, Japan). Animals were dosed orally with 
perampanel (2, 4, 8, or 16 mg/kg for rats; 0.5, 1, 2, or 4 mg/kg for mice) or vehicle, 1 hour 
prior to being placed on a rotating rod (rotation speed 6 rpm for rats, 8 rpm for mice), and 
the time animals were able to remain on the rod was recorded. Trial were conducted twice 
for each animal. Animals that failed to remain on the rotarod for 120 sec in both trials 
were classified as motor-uncoordinated. 
 
Complex partial seizures (Rat amygdala-kindling model) . 
Eight-week-old male Sprague Dawley rats obtained from SLC, Inc. (Shizuoka, Japan) 
were anaesthetized with pentobarbital (50 mg/kg) and a tri-polar electrode was inserted 
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into the amygdala complex using stereotaxic surgery. After a recovery period of 1 week, 
threshold current of afterdischarge was determined using a 25% ascending stimulation 
paradigm from 0.01 mA. Rats were stimulated at the threshold current once daily until ≥3 
consecutive stage 5 seizures were observed. Animals that showed stable threshold current 
of afterdischarge for at least 3 consecutive stimulations were selected for further 
experiments. 
Threshold current of afterdischarge was determined using an ascending stimulation 
schedule prior to administration of either perampanel or vehicle. A second threshold 
determination was performed 1 hour following oral administration of perampanel (1, 1.25, 
2.5, 5, or 10 mg/kg) or vehicle (0.5% methylcellulose). Afterdischarge duration, motor 
seizure duration (time with stage 4 and 5 seizure), and seizure severity (Racine 1972) 
were then determined in each rat using a stimulus that was two steps (or 50%) stronger 
than the afterdischarge threshold current.  
Racine severity scale; 
Score 1: immobility, facial clonus, eye closure, twitching of vibrissae, stereotyped 
sniffing 
Score 2: head nodding, severe facial clonus 
Score 3: unilateral forelimb clonus 
Score 4: rearing often accompanied by bilateral forelimb clonus 
Score 5: continuous rearing and falling accompanied by secondary generalized clonic 
seizure 
 
Spontaneous absence seizure model (genetic absence epilepsy in rats from Strasbourg 
(GAERS)). 
Eight GAERS from the French breeding colony (Université d’Orléans, France, 250-
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350g) were implanted with 5 monopolar stainless steel electrodes positioned over the 
frontal and parietal cortices, in both sides of the brain, under generalized anaesthesia 
(xylazine 0.5 ml/kg i.m. + ketamine 100 mg/kg, i.p.). The rats were equipped with a female 
connector fixed on the skull to allow chronic EEG recordings. Rats were injected 
systemically with vehicle, E2007 (1, 3 and 10 mg/kg/5ml, per p.o., dissolved in 0.5N HCl) 
and valproate (200 mg/kg/5ml, i.p., dissolved in saline) in a random order (one week 
between two injections) so that each animal was its own control. Digital EEG recordings 
were performed 20 min before the injection and during 120 min after the injection with 
fronto-parietal derivations. The general behaviour of the animals was observed during the 
recording period and rats were constantly monitored by an investigator to ensure that 
they did not fall asleep. 
 
Statistical analysis. 
In animal studies, ED50 (effective dose causing 50% reduction in seizures), TD50 (dose 
causing 50% reduction in motor coordination) and 95% CIs were calculated by regression 
analyses. Two-way ANCOVA (analysis of covariance) was used to assess overall effect of 
treatment, and Dunnett’s post test was used to compare differences between treatment 
groups in amygadala kindling study. Two-way ANOVA for repeated measures followed by 
Wilcoxon test for paired data was used in GAERS study. Differences between treatment 
groups were considered significant if the p-value was less than 0.05. 
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Results 
Generalized tonic-clonic seizures (MES-induced seizures). 
MES is animal model of human tonic-clinic seizure. This model was also utilized for 
primary screening model for the discovery of anticonvulsant. Perampanel clearly 
inhibited occurrence of tonic extension of hindlimb (ED50 1.6 mg/kg) suggesting potential 
utility in tonic-clonic seizure type (Table 5). 
 
Absence or myoclonic seizures (Pentylenetetrazole (PTZ)-induced seizures). 
PTZ model is considered animal model of absence or myoclonic seizure. It is also 
utilized for the evaluation of compound for characterization. Perampanel also inhibited 
occurrence of myoclonic seizure with an ED50 value at 0.94 mg/kg (Table 5). 
 
Reflex seizures (Audiogenic seizures). 
Audiogenic seizure is animal model of reflex seizure and often utilized for the drug 
screening. Perampanel also inhibited this seizure with and ED 50 value at 0.47 mg/kg 
(Table 5). 
 
Psychomotor seizures (6-Hz electroshock-induced seizures). 
The 6-Hz seizure is drug resistant seizure model especially for channel blockers. It is 
considered animal model of psychomotor seizures. Drug efficacy in this model is decreased 
when stimulus intensity is increased. Perampanel, given orally 1 hour prior to test, 
protected mice from 6 Hz electroshock-induced seizures in a dose-dependent manner 
(Figure 4). The ED50 value for perampanel was similar at 32 mA (ED50 2.1 mg/kg; 95% CI, 
1.4–2.9) and 44 mA (ED50 2.8 mg/kg; 95% CI, 2.0–4.2) stimulus intensities (Figure 4A). 
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Carbamazepine (20 mg/kg), phenytoin (10 mg/kg) and valproate (100 mg/kg) each further 
reduced the incidence of seizures in the presence of perampanel (Fig. 12). 
 
Effect on motor coordination (Rotarod test). 
The effect of perampanel on motor coordination was determined using the rotarod test. 
Perampanel caused dose-dependent motor impairment in both mice (TD50 1.8 mg/kg; 95% 
CI, 1.4–2.8; n = 9 per group) and rats (TD50 9.14 mg/kg; n = 8 per group). In mice, the 
protective index, defined as TD50 in rotarod test/ED50 in individual seizure tests, was 1.1, 
3.8, and 1.9 for MES-induced, audiogenic, and PTZ-induced seizures, respectively (Table 
5). 
 
Complex partial seizures (Rat amygdala-kindling model). 
Amygdala kindling is animal model of complex partial seizures. Perampanel, given 
orally 1 hour prior to test, significantly increased afterdischarge threshold in amygdala-
kindled rats at 10 mg/kg (Fig. 13), and significantly decreased motor seizure duration 
recorded at 50% higher intensity than after discharge threshold current stimulation at 5 
mg/kg or higher (Fig. 14C). Perampanel at 10 mg/kg also significantly decreased 
afterdischarge duration and seizure severity at 50% higher intensity than after discharge 
threshold current stimulation (Fig. 14A and 14B). 
 
Spontaneous absence seizure model (genetic absence epilepsy in rats from Strasbourg 
(GAERS)). 
Valproate injected at the dose of 200 mg/kg remarkably reduced SWD during the 100 
minutes following injection (reduction between 72 and 95% compared to reference period). 
Wilcoxon test for paired data revealed a significant effect between 0 and 100 min post 
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injection for cumulated duration of SWD, number of SWD (Fig. 15). After 100 min post-
injection level of SWD return to values not significantly different from vehicle. On the 
other hand, oral perampanel (1, 3 and 10 mg/kg) failed to changed parameters of the 
study (Fig. 15). No gross modifications of the animals’ behaviour or EEG activity were 
observed at tested doses. 
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Disucssion and Conclusion 
Perampanel inhibited seizures in both MES and PTZ models. The most of 
anticonvulsant utilized in the treatment for partial onset seizures inhibited MES but 
limited number of anticonvulsant works in PTZ model. It is generally considered that only 
the compound with clinical efficacy in myoclonus or absence seizure could inhibit seizures 
in PTZ model. In addition perampanel showed efficacy in audiogenic seizure. The results 
suggested that peramapnel could show broader clinical efficacy in patients with epilepsy.  
Seizures induced by 6 Hz electroshock are classically considered resistant to phenytoin 
and other inhibitors of voltage-dependent ion channels, with AED activity being closely 
linked to the stimulation intensity (Barton et al., 2001). Phenytoin and lamotrigine show 
only a partial inhibitory response when stimulation intensity is increased from 22 mA to 
32 mA in this model, whereas many other AEDs lose effectiveness when stimulation 
intensity increases further to 44 mA (Barton et al., 2001). In a test of seven established 
AEDs (phenytoin, carbamazepine, clonazepam, phenobarbital, ethosuximide, 
trimethadione and valproic acid) and five new generation AEDs (lamotrigine, 
levetiracetam, felbamate, tiagabine and topiramate), only levetiracetam and valproate 
showed activity in the 6 Hz model at 44 mA stimulation intensity, and in both cases, 
efficacy of the compounds was lower at 44 mA than at 32 mA stimulation intensity, as 
shown by higher ED50 values (Barton et al., 2001). In contrast, perampanel showed 
similar effectiveness at 32 mA and 44 mA stimulation intensities in our studies. 
Drug effects in amygdala kindling model have been shown to be predictive of effects on 
complex partial seizures with secondary generalization in humans. Perampanel increased 
afterdischarge threshold and significantly reduced motor seizure duration, afterdischarge 
duration, and seizure severity in the rat amygdala-kindling model. Thus, perampanel 
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inhibited both secondary generalized seizures (seizure score ≥4) and focal seizures (score 
≤3). Although most AEDs are reported to inhibit amygdala-kindled seizures, their effects 
differ significantly. Phenytoin, for example, appears to suppress focal seizures, but does 
not inhibit the spread of afterdischarges and the development of secondary generalized 
seizures (Ebert et al., 1997). In contrast, some NMDA receptor antagonists have been 
shown to block only generalized seizures in this model (Barton & White, 2004). AMPA 
antagonists, on the other hand, block both the focal and generalized components (Hara et 
al., 2006), consistent with characteristic broad spectrum antiseizure effects of these 
compounds. AMPA receptors are thought to play a critical role in the propagation of 
seizures (Namba et al., 1994; Rogawski & Donevan, 1999), and are also likely to be 
involved in their initial triggering (Tortorella et al., 1997). Interestingly, afterdischarge 
persisted in some perampanel-treated animals despite complete inhibition of behavioral 
seizures, suggesting that perampanel may have a greater inhibitory effect on propagation 
of seizures than on their initiation.  
Morimoto at al.(1997) described that increased stimulus intensity could make a 
condition that would be less sensitive to AEDs. Peramapnel reduced seizure severity in 
the condition with 50% higher stimulus intensity than after discharge threshold. It may 
suggest that perampanel inhibit severer seizure condition compared to others.  
Efficacy in GAERS showed difference from PTZ study. Difference of end point between 
two animal models (behavior or EEG) may affect the results. However, at least 
perampanel did not worsen SWD in GAERS. Some times AEDs could causes aggravation 
of seizure in patient with specific type of seizures. The most well-known case is 
aggravation of myoclonic or absence seizure by carbamazepine (Sazgar and Bourgeois, 
2005). This clinical phenomenon is also translated into animal model of absence seizure 
(Russo, 2011). Patients with epilepsy often have multiple seizure types. No seizure 
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aggravation was confirmed by the treatment with perampanel across animal models. It 
may connect to reduction of risk for patients experiencing seizure aggravation or 
appearance of new seizure types.  
Results from Rotarod test suggested that perampanel could cause motor impairment 
close the dose showing antiseizure effects. Similar effects on motor coordination have been 
reported for both noncompetitive (e.g. GYKI52466) and competitive (e.g. NBQX) AMPA 
receptor antagonists, suggesting a mechanism associated with AMPA receptor blockade 
(Yamaguchi et al., 1993). The window between antiseizure effects and motor dysfunction, 
however, is different across preclinical seizure models, making predictions of clinical 
therapeutic index difficult. Furthermore, AEDs such as gabapentin and pregabalin cause 
central nervous system (CNS) depressant effects in patients (Arroyo et al., 2004; Arroyo & 
Lesser, 1993), despite preclinical studies that indicated a very wide therapeutic margin 
(Dalby & Nielsen, 1997; Vartanian et al., 2006), whereas valproate shows a narrow 
therapeutic margin in rodent models (Barton et al., 2001), but does not show strong CNS 
depressant side effects (Mattson et al., 1992). Thus, clinical therapeutic index of AEDs 
cannot reliably be inferred from preclinical studies. 
Efficacy of perampanel in various seizure models are summarized in table 6. 
Perampanel showed antiseizure effect in most of seizure models and showed efficacy in 
severe seizure condition in 6Hz and amygdala kindling model. These could support utility 
in severe seizure condition like refractory partial onset seizure. It was proven in clinical 
studies. Regulatory authorities approved perampanel as adjunctive treatment of partial 
onset seizure. 
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Table 5. Effect of drugs on audiogenic, MES-, PTZ-induced seizure and motor 
coordination (rotarod test) in mice. 
 
 
 
 
 
 
Figure 12. Effect of perampanel on 6-Hz electroshock-induced seizure. 
The 6-Hz electroshock-induced seizure is considered as animal model of refractory 
psychomotor seizures. Perampanel or vehicle were orally administered one hour 
before test. The 6-Hz electroshock-induced seizure was evaluated with different 
stimulus intensities (32 mA, 44 mA, n=9 -10). Perampanel exerted anti-seizure 
effect in both stimulus intensity with similar ED50 values (32 mA, ED50 2.1 mg/kg; 
95% CI, 1.4–2.9; 44 mA, ED50 2.8 mg/kg; 95% CI, 2.0–4.2) 
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Figure 13. Effect of perampanel on seizure threshold in amygdala kindling model. 
Seizure threshold was determined by applying ascending electrical stimuli to the 
model. Appearance of more than 3 seconds after discharge was designated threshold 
of seizure. 
* for p<0.05 vs vehicle (ANCOVA followed by Dunnett’s test) 
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Figure 14. Effect of perampanel on seizure severity in amygdala kindling model. 
Seizure was elicited with electrical stimuli 50% stronger than threshold of seizure.  
Seizure severity according to Racine’s score (A), afterdischarge duration (B) and 
motor seizure duration (C, duration of score 4 and 5 seizure) was determined. 
* for p<0.05 vs vehicle (ANCOVA followed by Dunnett’s test) 
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Figure 15. Effect on spike wave discharge (SWD) in GAERS. 
A. Cumulative duration of SWD (s/20 min). B. Number of SWD (/20 min).  
Data are represented as mean ± SEM (n=8). * for p<0.05 vs vehicle (Wilcoxon test). 
VPA; Sodium Valproate, PER; Perampanel 
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Table 6. Effect of perampanel in various seizure models 
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Chapter IV: 
Therapeutic treatment in Status epilepticus 
Abstract 
The efficacy of diazepam, and the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptor antagonists, perampanel and GYKI52466 was assessed in 
a lithium-pilocarpine status epilepticus (SE) model. Combination therapy of diazepam 
and perampenl was also evaluated. SE was induced in rats using lithium chloride, 
scopolamine methyl bromide, and pilocarpine. Diazepam 10, 20, or 40 mg/kg , or 
perampanel 1, 2.5, 5, or 8 mg/kg were administered intravenously at 10 or 30 min after 
seizure onset, and GYKI52466 50 mg/kg , or combinations of diazepam 2.5–5 mg/kg and 
perampanel 0.5–1 mg/kg, were administered intravenously at 30 min after seizure onset. 
Diazepam 20 mg/kg terminated seizures (based on electroencephalography and 
assessment of behavioral seizures) in 2/6 rats at 10 min and 0/6 rats at 30 min (ED50: 10 
min, 30 mg/kg; 30 min, not determined). Perampanel 8 mg/kg terminated seizures in 6/6 
rats at both 10 and 30 min (ED50: 10 min 1.7 mg/kg; 30 min, 5.1 mg/kg). GYKI52466 50 
mg/kg terminated seizures in 2/4 rats at 30 min. Co-administration of diazepam 5 mg/kg 
and perampanel 1 mg/kg terminated seizures in 9/9 rats at 30 min. In conclusion, 
perampanel and GYKI52466 provided efficacy in a lithium-pilocarpine SE model at 30 
min after seizure onset, when SE was refractory to diazepam, supporting the therapeutic 
potential of AMPA receptor antagonists for refractory SE. The dose of perampanel and 
diazepam required to terminate seizures was much reduced by combination therapy, 
suggesting synergy.  
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Introduction 
Status epilepticus (SE) is a prolonged, self-sustained seizure that is associated with 
substantial mortality and morbidity (Hui et al., 2003; Shneker and Fountain, 2003; Chin 
et al., 2004). It is considered that SE is one of the most critical conditions among 
neurological emergency. 
Treatment of SE is started with denzodiazepines. If efficacy is limited, additional AEDs 
is used for the termination of seizure. However, SE is often refractory to treatment, 
increasing the risk of poor outcomes (Rossetti et al., 2005; Novy et al., 2010; Hocker et al., 
2013; Sutter et al., 2013). In a study of adults with SE, 22.6% of cases did not respond to 
first- or second-line treatments, and these cases were associated with higher mortality 
rates than non-refractory SE (39% versus 11%) (Novy et al., 2010). Refractory SE (RSE) 
can necessitate referral to an intensive care unit and treatment with anesthetizing AEDs, 
such as midazolam, propofol, or barbiturates, to help prevent severe acute systemic and 
long-term neuronal consequences (Meierkord et al., 2006; Meierkord et al., 2010; Brophy 
et al., 2012). 
SE is thought to be a consequence of dysfunction in the neuronal machinery required 
for the termination of seizures: specifically, a loss of inhibitory γ-amino butyric acid 
(GABA) neuronal activity coupled to sustained glutamate-mediated excitatory activity 
(Naylor et al., 2005; Chen and Wasterlain,, 2006; Naylor, 2010; Deeb et al., 2012). In the 
lithium-pilocarpine rat model of SE there is a functional loss of post-synaptic GABAA 
receptors approximately 1 h after seizure onset and this is associated with internalization 
of the receptor to the cytoplasm (Naylor et al., 2005). Loss of GABA-mediated inhibitory 
activity may also be a result of changes in chloride homeostasis, as the inhibitory effects 
of GABAA receptors are mediated by chloride flux (Chen and Wasterlain, 2006; Deeb et al., 
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2012). Anesthetizing AEDs that enhance GABA activity are currently used to treat RSE 
(Meierkord et al., 2006; Meierkord et al., 2010), but novel approaches targeting non-
GABAergic mechanisms may help to improve treatment outcomes. 
In animal studies, AMPA antagonist was shown efficacy of seizure termination in 
refractory condition to benzodiazepine (Pitkanen et al., 2007; Fritsch et al., 2010; Langer 
et al., 2011; Rajasekaran et al., 2012) .  
In a study of AMPA receptor-mediated neurotransmission in a lithium-pilocarpine rat 
model of SE, RSE was associated with a selective reduction in surface expression of the 
GluA2 subunit of the AMPA receptor on hippocampal membranes and an increase in 
GluA2 subunit internalization rates (Rajasekaran et al., 2012). This resulted in calcium-
permeable GluA2-lacking AMPA receptors with distinct biophysical characteristics, and 
continued neurotransmission. This synaptic plasticity may be an important 
pathophysiologic change in SE leading to subsequent neurodegeneration and increased 
mortality and morbidity. Therefore, inhibition of AMPA receptor activity may have 
potential as a therapeutic approach for the treatment of RSE. 
These suggested that perampanel could be an option to terminate status epilepticus. 
Here, efficacy of perampanel in Li-pilocarpine model of status epilepticus which is animal 
model of benzodiazepine refractory SE. In addition, pharmacodynamic interaction with 
diazepam was examined 
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Materials and Methods 
Animals. 
Male Sprague Dawley rats (Charles River Laboratories, Kanagawa, Japan) were used 
for seizure termination studies. All animals weighed weighing 240–400 g were housed in 
cages in a controlled environment (constant temperature 22 ± 1°C; humidity 50–60%; 12-h 
dark/light cycle [lights on 07:00 to 19:00 h]) with free access to food (MF diet; Oriental 
Yeast Co., Tokyo, Japan) and water. All experiments were approved by the Committee for 
the Welfare of Laboratory Animals of Eisai Co., Ltd. 
 
Reagents. 
Lithium chloride (Wako Pure Chemical Industries, Osaka, Japan), pilocarpine (Wako 
Pure Chemical Industries), and scopolamine methyl bromide (Sigma-Aldrich, Tokyo, 
Japan) were dissolved in 0.9% sodium chloride solution. Diazepam (Wako Pure Chemical 
Industries), perampanel (Eisai Co., Ltd, Kashima, Japan), and GYKI52466 (Sigma-RBI, 
St Louis, MO, USA) were prepared in 1:1:1 (v/v) distilled water, dimethyl sulfoxide, and 
polyethylene glycol 300.  
 
Surgical procedures for implantation of electrodes. 
Rats were acclimatized for at least 1 week prior to surgery. On the day of surgery, rats 
were anesthetized with pentobarbital 50 mg/kg (Somnopentyl injection; Kyoritsu Seiyaku, 
Tokyo, Japan) administered intraperitoneally (i.p.) and surface electroencephalography 
(EEG) electrodes (XR2C-2011-N; Omron, Kyoto, Japan) were positioned epidurally in the 
skull using stereotaxic surgery. One electrode was placed over the right somatosensory 
cortex (2.5 mm posterior from the bregma and 3.0 mm lateral to the midline) according to 
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the coordinates of Paxinos and Watson (2007), with another reference electrode placed 
over the right cerebellum. Electrodes were fixed to the skull with acrylic dental cement. 
After electrode implantation, rats were returned to their home cage and allowed to 
recover. 
 
Induction of status epilepticus. 
At least 1 week after implantation of EEG electrodes, and 16–24 h before pilocarpine 
treatment, rats were treated with lithium chloride 3 mEq/kg i.p. On the day of testing, 
rats were placed in acrylic boxes and baseline EEG was recorded (Lab Charts® 7 v7.2; AD 
Instruments, Sydney, Australia) for at least 10 min. Rats were then injected with 
scopolamine methyl bromide 5 mg/kg i.p. and pilocarpine 30 mg/kg i.p. The dose and 
timing of scopolamine methyl bromide injection was selected to confer inhibition of the 
peripheral side effects of pilocarpine (salivation, diarrhea, lacrimation), which was not 
achieved with the standard regimen of scopolamine methyl bromide 1 mg/kg, 
administered 30 min prior to pilocarpine. In addition, the selected regimen of 
scolpolamine methyl bromide appeared to reduce the potential for respiratory problems, 
which occasionally resulted in animal death, apparently due to the aspiration of saliva, 
when the standard regimen of scopolamine methyl bromide was used prior to the 
administration of high doses of perampanel or diazepam. The higher dose used here 
slowed seizure onset, but did not change the subsequent course of SE. Seizure onset was 
designated as the first spike train in EEG recording (not as the start of SE). 
 
Drug treatment. 
Diazepam, perampanel, and GYKI52466 were administered by bolus intravenous (i.v.) 
injection to the rat tail vein after seizure onset.  
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Diazepam has previously been shown to terminate or attenuate kainic acid-induced SE 
in rodents when administered 5 min to 2 h after seizure onset at doses of 20–25 mg/kg i.p. 
(Pitkanen et al., 2007; Fritsch et al., 2010); therefore a dose range of 10–40 mg/kg i.v. was 
selected for this study. Diazepam doses of 10, 20, or 40 mg/kg i.v. were administered to 
groups of six rats at 10 min after seizure onset. Doses of 20 or 40 mg/kg i.v. were also 
administered to six or seven rats, respectively, at 30 min after seizure onset. 
In pilot experiments using the lithium-pilocarpine rat model of SE, perampanel 8 mg 
kg-1 consistently terminated seizures and was well tolerated; therefore, a maximum dose 
of 8 mg kg-1 i.v. was selected for this study. Perampanel 1, 2.5, 5, or 8 mg/kg i.v. was 
administered at 10 min after seizure onset to groups of six rats each. Perampanel doses of 
2.5 or 5, 5 or 8 mg/kg i.v. were also administered at 30 min after seizure onset, and a dose 
of 8 mg/kg i.v. was administered at 30, 60, or 90 min, all to groups of six rats. 
 
Assessment of seizure termination. 
Seizures were considered terminated if EEG spike activity was abolished, EEGs were 
spike-free at 30 min after drug dosing, and there was a lack of behavioral seizures. 
Behavioral seizures were classified according to Racine (1972): stage 1 – immobility, eye 
closure, twitching of vibrissae, sniffing, facial clonus; stage 2 – head nodding associated 
with more severe facial clonus; stage 3 – clonus of one forelimb; stage 4 – rearing, often 
accompanied by bilateral forelimb clonus; stage 5 – all of the above plus loss of balance 
and falling, accompanied by generalized clonic seizures. 
 
Statistical analyses. 
Doses required to terminate seizures in 50% of animals (ED50) values and their 
statistical comparisons were calculated by computer probit analysis using SAS version 9.3 
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(SAS Institute, Tokyo, Japan). 
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Results 
Lithium-pilocarpine-induced status epilepticus.  
Approximately 15–30 min after pilocarpine administration, rats exhibited a train of 
spikes in EEG recordings that grew progressively larger (seizure onset; Fig. 16). 
Continuous EEG spikes and behavioral generalized seizures developed within 10 min of 
seizure onset, indicating establishment of SE, and were maintained for at least 180 min. 
Administration of vehicle (i.v.) did not affect the continuous EEG spikes. 
 
Diazepam monotherapy. 
When administered 10 min after seizure onset, diazepam terminated seizures at an 
ED50 of 30 mg/kg (95% confidence interval [CI], 17–130 mg kg-1; Table 1). A dose of 20 
mg/kg i.v. terminated EEG seizures in three two of six rats when administered at 10 min 
(Fig. 17A), and also conferred strong muscle relaxation, such that no visible behavioral 
seizures persisted. However, when administered 30 min after seizure onset, diazepam 20 
mg/kg i.v. failed to terminate EEG seizures, and a higher dose of 40 mg/kg was only 
effective in one of seven rats (Table 7, Fig. 17B). 
 
Perampanel monotherapy. 
Perampanel terminated seizures at an ED50 of 1.7 mg/kg (95% CI 0.3–3.8 mg/kg) when 
administered 10 min after seizure onset, and 5.1 mg/ kg (95% CI 4.9–5.2 mg/kg) when 
administered at 30 min (lack of overlap of 95% CI values indicates a significant reduction 
in efficacy between 10 and 30 min; Table 8). In contrast to diazepam, perampanel 8 mg 
/kg i.v. immediately terminated seizures in six of six rats whether administered at 10 or 
30 min (Fig. 18). 
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Combination therapy. 
Diazepam 20 mg/kg, perampanel 8 mg/kg, and GYKI52466 50 mg/kg caused strong 
CNS depressant effects (immobility, loss of righting reflex) during observation in all rats, 
with higher doses of diazepam and perampanel compromising respiration in some cases. 
Therefore, in an attempt to reduce CNS inhibition, the combination of lower doses was 
explored.  
When diazepam 5 mg/kg i.v. was administered in combination with perampanel 1 mg/kg 
i.v. at 30 min after seizure onset, seizures were terminated in all rats (n = 9, Fig 19, Table 
9). At lower doses, seizures were terminated in four of six rats (diazepam 2.5 mg/kg, 
perampanel 1 mg/kg) and two of six rats (diazepam 5 mg/kg, perampanel 0.5 mg/ kg) 
(Table 9). 
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Discussion and Conclusion 
In this lithium-pilocarpine rat model, continuous EEG spikes, indicative of the 
development of SE, were observed within 10 min of seizure onset. Diazepam i.v. 
terminated seizures at an ED50 of 30 mg/kg when administered 10 min after seizure onset. 
However, when administered at 30 min after seizure onset, no animals responded to 
diazepam 20 mg/kg, and only one of seven animals responded to diazepam 40 mg/kg, 
suggesting that refractoriness to benzodiazepine had started to develop by this time point. 
It is well recognized that pharmacoresistance to benzodiazepines develops rapidly in the 
lithium-pilocarpine rat model, and the current results appear to be in accordance with 
this. For example, diazepam 20 mg/kg was able to stop SE in the lithium-pilocarpine rat 
model when administered at the early stage of discrete electrographic seizures, but 
became less effective when administered at later stages of SE (Walton and Treiman, 1998). 
Similarly, it has been reported that diazepam i.p., at doses of up to 20 mg/kg, provided 
some efficacy at 10 minutes after the development of a stage 3 seizure in the lithium-
pilocarpine rat model, but not at later time points (Jones et al., 2002). 
In contrast, perampanel i.v. terminated seizures at an ED50 of 1.7 mg/kg when 
administered 10 min after seizure onset, and continued to provide efficacy at 30 min with 
an ED50 of 5.1 mg/kg. A dose of perampanel 8 mg/kg terminated seizures in all animals at 
30 min after seizure onset. These data are in accordance with previous studies of AMPA 
receptor antagonists in animal models of SE other than pilocarpine model (Pitkanen et al., 
2007; Fritsch et al., 2010; Langer et al., 2011; Rajasekaran et al., 2012) and support the 
potential efficacy of agents with this mechanism of action in benzodiazepine-refractory SE.  
Previous research using animals models of SE has indicated that repeated i.p. 
injections of GYKI52466 are required to terminate seizures (Fritsch et al., 2010), but a 
65 
 
single i.v. injection was sufficient to cease seizures in this study. This discrepancy may 
reflect the different administration routes, since i.v. administration may be expected to 
increase plasma concentrations more rapidly, and to a greater extent, than i.p. 
administration. 
SE has been associated with internalization of GABAA receptors to the cytoplasm at 
just 1 h after seizure onset (Naylor et al., 2005). In accordance with this, evidence from 
animal models also suggests that plastic changes in GABAA receptor function occur 
rapidly during the development of SE (Feng et al., 2008). Such functional changes have 
previously been associated with decreases in the sensitivity of SE to benzodiazepines over 
time in the lithium-pilocarpine rat model (Walton and Treiman, 1988; Kapur and 
Macdonald, 1997; Feng et al., 2008), as was observed with diazepam at the 30 min time 
point in the present study. In contrast, while expression of the AMPA receptor subunit 
GluA2 has been found to be reduced in SE, similar receptor function may be provided by 
GluA2-lacking AMPA receptors (Rajasekaran et al., 2012). This is consistent with our 
findings that AMPA receptor antagonists continue to provide efficacy for the treatment of 
SE at 30 min and beyond.  
However, the efficacy of perampanel appeared to wane over time, as the ED50 value for 
the termination of seizures was greater when perampanel was administered 30 min after 
seizure onset than when it was administered at 10 min. Given these timings, and the 
potential interactions of the GABA and AMPA systems indicated by the synergistic effects 
of co-administering perampanel and diazepam, such a decline in efficacy may be 
associated with the early changes in GABAA receptor function.  
Diazepam 20 mg/kg, perampanel 8 mg/kg, and GYKI52466 50 mg/kg caused strong 
CNS depressant effects (immobility, loss of righting reflex) in all rats. Although such 
effects may be justified by the termination of SE, it is important to explore approaches to 
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improve tolerability while maintaining efficacy. High doses of AEDs have been associated 
with substantial toxicity in animal models (Morimoto et al., 1997), and we therefore 
hypothesized that administration of lower doses of perampanel might be useful in 
optimizing safety outcomes. Combination therapy was explored as an option to reduce 
dosing because synergistic effects have previously been reported with AEDs in the 
lithium-pilocarpine model, including diazepam in combination with N-methyl-D-aspartate 
receptor antagonists (Rice and DeLorenzo, 1999; Martin and Kapur, 2008). We report that 
seizures were consistently terminated in the lithium-pilocarpine rat model by the co-
administration of low doses of diazepam (5 mg/kg) and perampanel (1 mg/kg) at 30 min 
after seizure onset, similar to the efficacy observed at this time point with perampanel 8 
mg/kg alone. Although CNS depressant effects were observed with both approaches, 
recovery of righting reflex occurred more quickly with the low-dose combination therapy. 
These results indicate synergistic effects that may reduce the required therapeutic dose of 
perampanel in the presence of diazepam, conferring improved safety outcomes. Similarly, 
a subclinical dose of the AMPA antagonist LY-300164 has been shown to significantly 
inhibit seizures in amygdala-kindled seizure models when combined with low-dose 
benzodiazepines, but the combination did not cause the motor impairment or memory 
deficits observed with higher-dose benzodiazepine monotherapy (Borowicz et al., 1999; 
Borowicz et al., 2000). 
Oral perampanel has been found to reduce the incidence of 6-Hz electroshock-induced 
seizures in mice at doses of 1–8 mg/kg, with lower doses required to achieve similar 
efficacy when co-administered with carbamazepine, phenytoin, or valproate. However, in 
our lithium-pilocarpine SE model, there were no such interactions between perampanel 2 
mg/kg and phenytoin 50 mg/kg (n = 4), and only a weak interaction between perampanel 2 
mg/kg and valproate 300 mg/kg (seizures terminated in 2/6 rats; data not shown). 
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Therefore, synergistic effects may depend on the seizure type and condition, and the 
interactions between perampanel and diazepam observed in the present study may be 
specific to benzodiazepine-resistant SE. 
As yet, there are no established therapies for RSE that directly attenuate neuronal 
excitation through the inhibition of glutamate receptors, with current guidelines 
recommending the use of anesthetizing AEDs that enhance GABA activity (Meierkord et 
al., 2006; Meierkord et al., 2010). However, studies using the lithium-pilocarpine rat 
model support the further investigation to elucidate a role of AMPA receptor antagonists 
in the treatment of RSE. 
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Figure 16. Representative electroencephalogram (EEG) of Lithium–Pilocarpine 
model of status epilepticus and outline of drug treatment.  
First spike train was designated as onset of seizure. Drugs was administered 
intravenously at designated timing after seizure onset.  This EEG trace was from 
the rat treated with vehicle. No major effect on EEG was observed. Seizure activity 
was persisted during experiment. 
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Figure 17. Efficacy of diazepam on EEG seizure in Li-Pilocarpine status epilepticus.  
A. Representative EEG trace from the rat treated with diazepam 10 minutes after 
seizure onset. Diazepam terminated EEG seizure soon after treatment in some rats.  
B. Diazepam treatment at 30 minuets after seizure onset did not terminate EEG 
seizure in all tested rats. 
 
 
Table 7. Number of treatment responder after diazepam treatment. 
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Figure 18. Efficacy of perampanel on EEG seizure in Li-Pilocarpine-induced status 
epilepticus.  
Perampanel at 8 mg/kg successfully terminated EEG seizure at 10 minutes (A) and 
30 minutes (B) after seizure onset.  
PER, perampanel 
 
 
Table 8. Number of treatment responder after perampanel treatment 
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Figure 19. Representative trace of EEG seizure in Li-pilocarpine –induced seizures.  
Perampanel and diazepam was co-administered at 30 minutes after seizure onset.  
PER, perampnael; DZP, diazepam 
 
 
 
 
 
Figure 9. Effect of combined treatment with perampanel and diazepam on lithium-
pilocarpine-induced seizures when administered intravenously 30 min after seizure 
onset. 
PER, perampnael 
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Chapter V: 
Conclusion 
Perampanel is the first market available AMPA antagonist claimed for the treatment of 
partial onset seizure adjunctive to other AEDs. Problem of AMPA antagonist in drug 
discovery and development was narrow therapeutic window as an extension of 
pharmacological effect in addition to chemical structure related drawbacks. From the 
middle of 1980’s, pharmaceutical companies had been tried to discover new AMPA 
antagonist for the treatment of various neurological diseases. However the most of 
discovered chemical structure had problems as CNS drug. Problem of competitive 
antagonist was poor blood brain barrier permeability resulting very high peripheral 
concentration connecting to peripheral safety issues. Prototype non-competitive 
antagonist showed favorable blood brain barrier permeability but short half life time in 
living body emphasized pharmacology related side effects at therapeutic doses. New 
chemical structure with favorable property as CNS drug was required to maximize the 
potential of target mode of action. We found new chemical template by high through put 
screening. It was a compound with small molecular weight therefore we believed that it 
had a large room to modify chemical structure to improve activity and property as drug. 
Medicinal chemistry effort identified 1,3,5-triaryl-1H-pyridin-2-one structure which 
showed potent AMPA antagonist property and good chemical tractability. It led discovery 
of perampanel (2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile). 
Perampanel showed strong in vitro activity against AMPA receptor and good AMPA 
antagonistic effect in animal. Furthermore, perampanel showed favorable metabolic 
stability in assay with human liver microsome.  
AEDs are generally utilized for the prevention of seizure attack. Pharmacology studies 
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in seizure models indicated that perampanel have broader antiseizure profile than most 
of other AEDs. It is favorable to reduce the risk of paradoxical exacerbation of seizure in 
epilepsy patients. It is also demonstrated that perampanel could protect the animal from 
the severer seizure. These characters seemed favorable to treat the patients with 
refractory epilepsy. However, therapeutic window between antiseizure effect and motor 
impairment indicated narrow therapeutic margin similar to known AMPA antagonists. 
While, metabolic stability in human liver microsome assay and pharmacokinetic 
parameters in animal suggested that perampanel could have very long half-life time in 
human. It was considered beneficial for development of tolerance in human like other 
CNS drugs. We considered that this could balance issues between tolerability and efficacy. 
This idea was proven through clinical study in epilepsy and approved as an AED in many 
countries. 
Perampanel also showed seizure terminative effect in animal model of refractory SE. It 
is quite similar property to other AMPA antagonists. There is an idea to treat refractory 
SE with drug combination therapy to improve outcome. It was recognized that 
combination therapy with benzodiazepine and ketamine could show pharmacodynamic 
interaction (Rice and DeLorenzo, 1999; Martin and Kapur, 2008) however combination of 
benzodiazepine and AMPA antagonist had not been demonstrated yet. Combination 
therapy of perampanel with diazepam exerted very prominent seizure terminative effect 
than that of monotherapy. Combination of perampanel and diazepam could be considered 
a reliable treatment for seizure termination in drug refractory SE. Further evaluation of 
this possibility is warranted.  
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